title: Axitinib.
abstract: In patients with advanced-stage or metastatic kidney cancer, interferon alfa, a cytokine, prolongs survival by about 4 months, and sunitinib, a tyrosine kinase inhibitor, by about 9 months. When interferon alfa fails, sorafenib, another tyrosine kinase inhibitor, appears to prolong survival by an additional 3 months. There is currently no treatment that prolongs survival after failure of sunitinib.
mesh_terms: D000077784:Axitinib; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007191:Indazoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib